This is a randomized, placebo and active-control, multiple-dose, phase IIa trial. Patients
were randomly assigned to receive HS-20094 (12 patients), placebo (3 patients), or active
control drug Semaglutide injection (3 patients) in a 4:1:1 ratio to each of four dose cohorts
of 5 mg, 10 mg, 15 mg, and 20 mg. HS-20094 and placebo were administered in a double-blind
design by subcutaneous injection once a week for a total of four times, and the dose was
gradually increased weekly (2.5-2.5-5-5 mg, 5-510-10 mg, 5-10-15-15 mg, 5-10-15-20 mg). The
active control drug semaglutide was administered by open-label, titrated subcutaneous
injection once a week for a total of four times, and the dose was increased gradually every
week until 1.0 mg (0.25-0.5-0.5-1.0 mg). The primary study objective was to 1) Evaluate the
safety and tolerability of multiple subcutaneous injections of HS-20094 in subjects with type
2 diabetes mellitus (T2DM) with or without overweight or obesity;2) Evaluate the
pharmacokinetics, pharmacodynamics and immunogenicity of multiple subcutaneous injections of
HS-20094.